Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Bioinformatics Market Potential

Vaccine Research & Development 2009

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Advanced Wound Management Pipeline Technology and Market Forecasts to 2015

Artificial Disc Replacement Pipeline Technology and Market Forecasts to 2015

Brazil Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Brazil Orthopedic Devices Market Analysis and Forecasts to 2015

Canada Anesthesia and Respiratory Devices Market Analysis and Forecasts to 2015

Canada Diabetes Care Devices Market Analysis and Forecasts to 2015

Canada Medical Equipment Market Analysis and Forecasts to 2015

Cardiac Assist Devices Pipeline Technology and Market Forecasts to 2015

China Medical Equipment Market Analysis and Forecasts to 2015

Chronic Diseases on the Rise: Personal Health Systems to Play a Key Role in Disease Management

BioPortfolio | PharmaVentures Reports | Effective Deal Making in Drug Delivery

Effective Deal Making in Drug Delivery

"Looming patent expiry a major force in driving valuation"

Drugs with annual sales totalling over US$86 B in 2007 are due to go off patent by 2012. Therefore, the application of novel drug delivery technologies to such existing therapeutics is an attractive means of prolonging the commerical viability of marketed drugs.

Technologies are more difficult to value than products in clinical development because the technical risks or success rates are less well documented, and costs and timescales are less predictable.

It is very important to benchmark when valuing technologies and to have a thorough understanding of the risks and rewards.

This new PharmaDeals® Report, covers the range of strategies and offerings available to the deal maker, and is vital for understanding growth and survival in volatile markets.

Drug delivery continues to be an increasingly important sector in the pharmaceutical industry and an area in which effective deal making is essential for survival and growth. A great proportion of small companies specialising in drug delivery systems rely upon deals for revenues, and larger pharmaceutical companies need access to their expertise and innovative technologies for the development of new products.

A third category comprises drug delivery companies that have transitioned into fully integrated pharmaceutical companies. The market is attractive: the market for drugs using special delivery systems has grown from $26 B in 2000 to over $60 B in 20061 and now accounts for over one tenth of the total pharmaceutical market.

Effective deal making is particularly important in the present economic climate with western economies experiencing a signifi cant downturn compared to recent years. A marked loss of confi dence in equity markets has continued to weaken public share offerings such that they are not currently viewed as an attractive means of raising the money that is required for rapid growth of drug delivery companies.

Indeed, following the burst of the technology bubble in 2001 and the subsequent drop of market indices, 2006 and 2007 showed some slow recovery. For example, NASDAQ posted 88% and 92% of the 2001 value in 2006 and 2007, respectively, but has slipped back in the fi rst 6 months of 2008 to 2005 levels. By the second half of 2008, the biotech/pharma IPO window has completely shut down and markets have dropped dramatically. The pharmaceutical and biotech sectors have a tendancy to operate in something of a bubble, and whilst not experiencing the dramatic downturns of other sectors, there has nonetheless been signifi cant drops and the drug delivery sector appears to have been hit particularly hard. As a result there has been even more pressure on dealmakers to strike the right deals and strategic alliances to fuel growth. The rapid rise in the number and value of deals recorded in PharmaVentures' PharmaDeals® v2 Agreements Database shows the increasing reliance upon the development of strategic alliances for gaining access to innovation and the funds that are required for product development and corporate expansion.

Effective Deal Making in Drug Delivery encompasses issues that are vitally important to successful deal making within the drug delivery sector. The report begins with an assessment of the current and evolving drug delivery market, drug delivery companies and the challenges that are facing the drug delivery sector.

The key driving factors that underlie the drug delivery sector are considered, including improving the therapeutic index of drugs, improving patient benefi t and compliance, increasing the length of patent protection and product life cycle management. The report also reviews the business strategies that are employed for the commercialisation of drug delivery systems and an in-depth analysis addresses drug delivery alliances and their fi nancial terms.

Integral to this report is a searchable management tool, available via the PharmaDeals® web site, which comprises over 29,000 deals that occurred from May 1996 to the end of the third quarter of 2008. This comprehensive source of drug delivery deals enables the gathering of competitive deal information including financial information. In addition, the database assists in obtaining knowledge of company relationships and partnerships that are vital to most drug delivery companies' strategic business objectives.

The report also examines the drug delivery deal making activity of the top 10 pharmaceutical companies by healthcare sales, to help the reader understand the partnering activities of the largest healthcare companies. The valuation methodologies that can be used when formulating deal terms are also described, including principles and rationale, deal benchmarking and financial spreadsheet modelling.

The report includes an account of the process by which drug delivery deals are typically established from the initial steps of identifying the corporate needs, business opportunities and potential partners, through to the establishment of feasibility studies and full commercial alliances. Additionally, examples of genuine drug delivery agreements are provided that cover a variety of deal types including clinical & commercial, marketing, mergers & acquisition and finance deals. These agreements, less the redacted portions, can be accessed via the PharmaDeals® v2 Agreements database.

Print Copy ISBN 978-0-9558821-5-9. Prices for the pdf copy and site licences are available upon request.

January 2009

Print Copy ISBN 978-0-9558821-5-9.

Price: USD 5975

PDF ISBN 978-0-9558821-6-6

Price: USD 8970 Single User License

Table of Contents
Brochure and Sample Pages

Format

Type

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions